Are There Any Challenges in Targeting Replicative Immortality?
Yes, there are significant challenges. Cancer cells are highly adaptable and may develop resistance to therapies targeting telomerase or ALT. Additionally, telomerase is also active in certain normal cells, such as stem cells and germ cells, so inhibiting it could have detrimental effects on normal tissue function. Therefore, any potential treatment must be carefully designed to specifically target cancer cells while sparing normal cells.
